Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.

Yu X, Xu J, Cao J, Xu Q, Chen H, Yu D, Yao X, Chen K, Ma L

American journal of cardiovascular drugs : drugs, devices, and other interventions15 Sept 2025Cited by 3 (Europe PMC)

PMID40954388PMCIDPMC12779688DOI10.1007/s40256-025-00764-7PepBankPUB-40954388

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NAD+ improved LVEF more than placebo at one month.
In plain wordsIn adults with ischemic cardiomyopathy, NAD+ improved heart pumping function more than placebo at one month.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
IncreaseLVEF at one month
Study
n = 180
Comparator
placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Measurements
LVEF
45.44%
NAD+ group, 1 month
LVEF
42.44%
placebo group, 1 month
Reported +/- uncertainty of LVEF (type not stated)
8.55%
NAD+ group, 1 month
Reported +/- uncertainty of LVEF (type not stated)
9.09%
placebo group, 1 month
P value for LVEF comparison
0.024 unitless
NAD+ versus placebo, 1 month
Source sentences
Summary
At 1 month, the NAD+ group demonstrated a significantly greater improvement in LVEF compared to the placebo group (45.44 ± 8.55% vs. 42.44 ± 9.09%, p = 0.024).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438801
02HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NAD+ showed a nonsignificant trend toward lower NT-proBNP versus placebo.
In plain wordsIn adults with ischemic cardiomyopathy, NT-proBNP tended to be lower with NAD+ than placebo, without statistical significance.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
No significant changeNT-proBNP at day seven
Study
n = 180
Comparator
placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Measurements
NT-proBNP
1471 pg/mL
NAD+ group, day 7, median (IQR 828.00-2950.00)
NT-proBNP
2317.5 pg/mL
placebo group, day 7, median (IQR 1155.00-4752.50)
Reported bracketed interval for NT-proBNP (type not stated)
828 to 2950 pg/mL
NAD+ group, day 7
Reported bracketed interval for NT-proBNP (type not stated)
1155 to 4752.5 pg/mL
placebo group, day 7
P value for NT-proBNP comparison
0.102 unitless
NAD+ versus placebo, day 7
Source sentences
Summary
A trend towards decreased NT-proBNP levels was observed in the NAD+ group at day 7 (1471.00 [828.00-2950.00]pg/mL vs. 2317.50 [1155.00-4752.50]pg/mL, p = 0.102).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438802
03HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NAD+ showed a nonsignificant trend toward fewer composite MACCE events versus placebo.
In plain wordsIn adults with ischemic cardiomyopathy, composite cardiac and stroke events tended to be fewer with NAD+ than placebo, without statistical significance.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
No significant changeComposite MACCE
Study
n = 180
Comparator
placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Measurements
6-month composite MACCE rate
14.6%
NAD+ group
6-month composite MACCE rate
24.7%
placebo group
P value for 6-month composite MACCE rate comparison
0.089 unitless
NAD+ versus placebo, 6 months
Source sentences
Summary
The 6-month composite MACCE rate appeared lower among those receiving NAD+ treatment compared to the placebo group (14.6% vs. 24.7%, p = 0.089), primarily driven by a trend toward fewer first unplanned HF hospitalizations (13.5% vs. 23.6%, p = 0.078).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438803
04HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NAD+ showed a nonsignificant trend toward fewer first unplanned HF hospitalizations versus placebo.
In plain wordsIn adults with ischemic cardiomyopathy, unplanned heart failure admissions tended to be fewer with NAD+ than placebo, without statistical significance.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
No significant changeFirst unplanned HF hospitalization
Study
n = 180
Comparator
placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Measurements
first unplanned HF hospitalization rate
13.5%
NAD+ group, 6 months
first unplanned HF hospitalization rate
23.6%
placebo group, 6 months
P value for first unplanned HF hospitalization rate comparison
0.078 unitless
NAD+ versus placebo, 6 months
Source sentences
Summary
The 6-month composite MACCE rate appeared lower among those receiving NAD+ treatment compared to the placebo group (14.6% vs. 24.7%, p = 0.089), primarily driven by a trend toward fewer first unplanned HF hospitalizations (13.5% vs. 23.6%, p = 0.078).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438804
05HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NYHA improvement was numerically more frequent with NAD+ than placebo at one month, without statistical significance.
In plain wordsIn adults with ischemic cardiomyopathy, NYHA improvement tended to be more frequent with NAD+ than placebo at one month, without statistical significance.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
No significant changeNYHA improvement at one month
Study
n = 180
Comparator
placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Measurements
NYHA class improvement
73%
NAD+ group, 1 month
NYHA class improvement
57.3%
placebo group, 1 month
P value for NYHA functional class improvement comparison
0.088 unitless
NAD+ versus placebo, 1 month
Source sentences
Summary
Additionally, a greater proportion of patients in the NAD+ group demonstrated improvement in NYHA functional class at both 1 month (73.0% vs. 57.3%, p = 0.088) and 6 months (53.9% vs. 39.3%, p = 0.115).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438805
06HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NYHA improvement was numerically more frequent with NAD+ than placebo at six months, without statistical significance.
In plain wordsIn adults with ischemic cardiomyopathy, NYHA improvement tended to be more frequent with NAD+ than placebo at six months, without statistical significance.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
No significant changeNYHA improvement at six months
Study
n = 180
Comparator
placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Measurements
NYHA class improvement
53.9%
NAD+ group, 6 months
NYHA class improvement
39.3%
placebo group, 6 months
P value for NYHA functional class improvement comparison
0.115 unitless
NAD+ versus placebo, 6 months
Source sentences
Summary
Additionally, a greater proportion of patients in the NAD+ group demonstrated improvement in NYHA functional class at both 1 month (73.0% vs. 57.3%, p = 0.088) and 6 months (53.9% vs. 39.3%, p = 0.115).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438806
07HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NAD+ did not significantly change left ventricular end-diastolic diameter versus placebo.
In plain wordsIn adults with ischemic cardiomyopathy, NAD+ did not significantly change left ventricular end-diastolic diameter compared with placebo.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
No significant changeLeft ventricular end-diastolic diameter
Study
n = 180
Comparator
placebo
Outcome group
Heart function · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Source sentences
Summary
No significant differences were observed in structural parameters (left ventricular end-diastolic diameter, left ventricular end-diastolic volume, left atrial diameter).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438807
08HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NAD+ did not significantly change left ventricular end-diastolic volume versus placebo.
In plain wordsIn adults with ischemic cardiomyopathy, NAD+ did not significantly change left ventricular end-diastolic volume compared with placebo.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
No significant changeLeft ventricular end-diastolic volume
Study
n = 180
Comparator
placebo
Outcome group
Heart function · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Source sentences
Summary
No significant differences were observed in structural parameters (left ventricular end-diastolic diameter, left ventricular end-diastolic volume, left atrial diameter).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438808
09HumanRandomized controlled trialEfficacy outcome
In adults with ischemic cardiomyopathy, NAD+ did not significantly change left atrial diameter versus placebo.
In plain wordsIn adults with ischemic cardiomyopathy, NAD+ did not significantly change left atrial diameter compared with placebo.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
No significant changeLeft atrial diameter
Study
n = 180
Comparator
placebo
Outcome group
Heart function · Cardiovascular
Studied dose
10 mg/day · intravenous · 7 daysAs given in this study (human).
Source sentences
Summary
No significant differences were observed in structural parameters (left ventricular end-diastolic diameter, left ventricular end-diastolic volume, left atrial diameter).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III.
Summary · context
Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy.
Report a problemFND-4095438809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.